Duo Rui Pharmaceutical

Nanjing-based Frontier Biotechnologies Inc. is poised to divest a 70% stake in its peptide active pharmaceutical ingredients (APIs) division to Tibet Duo Rui Pharmaceutical Co., Ltd. for RMB 10 million. Following the transaction, the API unit will establish a supply relationship with Frontier, with a separate purchase agreement to be…